Effects of genetic background on tumorigenesis in p53‐deficient mice
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Mice with disrupted germline p53 alleles have been engineered by us and others and have been shown to have enhanced susceptibility to spontaneous tumors of various types. We monitored a large number of p53‐deficient mice(p53+/− and p53−/−) and their wild‐type littermates(p53+/+) of two different genetic backgrounds(129/5v and mixed C57BL/6 × 129/5v) up to 2 yr of age.p53+/− and p53−/− 129/Sv mice show accelerated tumorigenesis rates compared with their p53‐deficient counterparts of mixed C57BL/6 × 129/Sv genetic background. The tumor spectra of the two strains of mice are similar except that almost half of 129/Sv p53−/− males develop malignant teratomas, whereas these tumors are rarely observed in C57BL/6 × 129/Sv mice and never in 129/Sv p53+/− males. In the study reported here, we further characterized the lymphomas that arose in the p53‐nullizygous mice and found that over three‐quarters of the lymphomas were of thymic origin and contained primarily immature(CD4+/CD8+) T‐cells, whereas the remainder originated in the spleen and peripheral lymph nodes and were of B‐cell type. The high incidence of early‐onset lymphomas in the nullizygous mice makes these animals a good lymphoma model, whereas the heterozygous mice may be a useful model for Li‐Fraumeni syndrome, a human inherited cancer predisposition.© 1995 Wiley‐Liss, Inc
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Extensive aCGH studies on human cancers using a variety of platforms have revealed widespread focal amplifications and deletions in human cancers which are now known to harbor oncogenes and tumor suppressor genes, respectively (113).”
From Telomeres and telomerase in cancer (2010) · cites this paper as [113]
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Self-citationGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542
Self-citationKemp, C. J., Donehower, L. A., Bradley, A., & Balmain, A. (1993) · Cell · doi:10.1016/0092-8674(93)90461-x · Cited by 457
Self-citationLavigueur, A., Maltby, V, Mock, D., Rossant, J., Pawson, T., & Bernstein, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.9.3982 · Cited by 394
Spontaneous Testicular Teratomas in an Inbred Strain of Mice
Stevens, L. C., & Little, C. C. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.11.1080 · Cited by 379
Research works printed but not linked: 1
- Stevens LC, 1979, Inbred and Genetically Defined Strains of Laboratory Animals: Mouse and Rat, 207
Cited by
Items 101–200 of 251
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner
Haupt, S., Mitchell, C., Corneille, V., Shortt, J., Fox, S. B., Pandolfi, P. P., Castillo-Martín, M., Bonal, D. M., Cordon-Carlo, C., Lozano, G., et al. (2013) · Cell Cycle · doi:10.4161/cc.24805 · Cited by 29
Tumor promotion by caspase-resistant retinoblastoma protein
Borges, H. L., Bird, J., Wasson, K., Cardiff, R. D., Varki, N. M., Eckmann, L., & Wang, J. Y. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503925102 · Cited by 36
Involvement of p53 in X-ray induced intrachromosomal recombination in mice
Aubrecht, J., Secretan, B., Bishop, A. J. R., & Schiestl, R. H. (1999) · Carcinogenesis · doi:10.1093/carcin/20.12.2229 · Cited by 32
Dysregulation of the mTOR pathway in p53-deficient mice
Leontieva, O. V., Novototskaya, L. R., Paszkiewicz, G., Komarova, E. A., Gudkov, A. V., & Blagosklonny, M. V. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26947 · Cited by 33
Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice
Donehower, L. A. (2014) · Human Mutation · doi:10.1002/humu.22507 · Cited by 29
Self-citationA Mouse Model of Uterine Leiomyosarcoma
Politi, K. A., Szabolcs, M. J., Fisher, P. E., Kljuic, A., Ludwig, T. E., & Efstratiadis, A. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63122-7 · Cited by 30
p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP
Madapura, H. S., Salamon, D., Wiman, K. G., Laín, S., Klein, G., Klein, E., & Nagy, N. (2012) · Cell Cycle · doi:10.4161/cc.22810 · Cited by 29
Deficiency of Splicing Factor 1 Suppresses the Occurrence of Testicular Germ Cell Tumors
Zhu, R., Heaney, J. D., Nadeau, J. H., Ali, S., & Matin, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0820 · Cited by 31
BALB/c alleles for Prkdc and Cdkn2a interact to modify tumor susceptibility in Trp53+/- mice.
Blackburn, A. C., Brown, J. S., Naber, S. P., Otis, C. N., Wood, J. T., & Jerry, D. J. (2003) · PubMed · Cited by 34
Semenza, J. C., & Weasel, L. H. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.97105s1155 · Cited by 31
Role of the p53 Family in Stabilizing the Genome and Preventing Polyploidization
Talos, F., & Moll, U. M. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6199-0_5 · Cited by 35
Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis
Bado, I., Nikolos, F., Rajapaksa, G. K., Wu, W., Castañeda, J., Krishnamurthy, S., Webb, P., Gustafsson, J.-Α., & Thomas, C. G. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0872-z · Cited by 27
Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review
Lone, W., Alkhiniji, A., Umakanthan, J. M., & Iqbal, J. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0460-z · Cited by 26
Influence of Hoxa5 on p53 Tumorigenic Outcome in Mice
Gendronneau, G., Lemieux, M., Morneau, M., Paradis, J., Têtu, B., Frenette, N., Aubin, J., & Jeannotte, L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090499 · Cited by 25
Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin
Robanus-Maandag, E. C., Giovannini, M., van der Valk, M., Niwa‐Kawakita, M., Abramowski, V., Antonescu, C., Thomas, G. D., & Berns, A. J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207858 · Cited by 24
Wong, K. S., Li, Y., Howard, J., & Ben‐David, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202938 · Cited by 26
P53 null mice: damaging the hypothesis?
Sansom, O. J., & Clarke, A. R. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00089-0 · Cited by 29
Shirai, N., Tsukamoto, T., Yamamoto, M., Iidaka, T., Sakai, H., Yanai, T., Masegi, T., Donehower, L. A., & Tatematsu, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.9.1541 · Cited by 22
Chromium(VI) Induces p53-Dependent Apoptosis in Diploid Human Lung and Mouse Dermal Fibroblasts
Carlisle, D. L., Pritchard, D. E., Singh, J. V., & Patierno, S. R. (2000) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200006)28:2<111::aid-mc7>3.0.co;2-y · Cited by 91
Self-citationStochastic modelling of tumorigenesis in p53 deficient mice
Mao, J., Lindsay, K., Balmain, A., & Wheldon, T. E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.40 · Cited by 23
Primary Neoplasms of Bones in Mice: Retrospective Study and Review of Literature
Kavirayani, A. M., Sundberg, J. P., & Foreman, O. (2011) · Veterinary Pathology · doi:10.1177/0300985811398252 · Cited by 21
A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation
Kazantseva, M., Mehta, S. Y., Eiholzer, R. A., Hung, N. A., Wiles, A. K., Slatter, T. L., & Braithwaite, A. W. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9758-3 · Cited by 23
Álvarez-Quilón, A., Terrón-Bautista, J., Delgado‐Sainz, I., Serrano-Benítez, A., Romero‐Granados, R., Martínez‐García, P. M., Jimeno-González, S., Bernal‐Lozano, C., Quintero, C., Garcia‐Quintanilla, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14638-w · Cited by 20
Hansen, S. A., Hart, M. L., Busi, S. B., Parker, T. W., Goerndt, A., Jones, K. B., Amos-Landgraf, J. M., & Bryda, E. C. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.025767 · Cited by 21
Mouse Models of Human Familial Cancer Syndromes
Ward, J. M., & Devor-Henneman, D. E. (2004) · Toxicologic Pathology · doi:10.1080/01926230490424680 · Cited by 23
Aging and cancer in transgenic and mutant mice
Anisimov, V. N. (2003) · Frontiers in bioscience · doi:10.2741/1122 · Cited by 19
The Evolution of Tumors in Mice and Humans with Germline p53 Mutations
Levine, A. J., Chan, C. S., Dudgeon, C., Puzio‐Kuter, A. M., & Hainaut, P. L. (2015) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2015.80.027631 · Cited by 19
Chang, P. Y. (2001) · Mutagenesis · doi:10.1093/mutage/16.1.7 · Cited by 18
Oncogenes in immune cells as potential therapeutic targets
Zakiryanova, G. K., Wheeler, S., & Shurin, M. R. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s150586 · Cited by 21
Levitt, P. S., Zhu, M., Cassano, A., Yazinski, S. A., Liu, H., Darfler, J. H. L., Peters, R. M., & Weiss, R. S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01763-06 · Cited by 33
Targeted Deletion of p73 in Mice Reveals Its Role in T Cell Development and Lymphomagenesis
Nemajerová, A., Palacios, G. F., Nowak, N. J., Matsui, S., & Petrenko, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007784 · Cited by 18
Genetic interactions between the Wilms' tumor 1 gene and the p53 gene.
Menke, A. L., Clarke, A. R., Leitch, A., IJpenberg, A., Williamson, K. A., Spraggon, L., Harrison, D. J., & Hastie, N. D. (2002) · PubMed · Cited by 18
Storer, R. D. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00227-1 · Cited by 18
Ridgeway, A. G., McMenamin, J., & Leder, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209391 · Cited by 17
cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response
Madapura, H. S., Salamon, D., Wiman, K. G., Laín, S., Klein, E., & Nagy, N. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1160975 · Cited by 18
Toxicology and Carcinogenesis Study of Senna in C3B6.129F1- Trp53 tm1Brd N12 Haploinsufficient Mice
Surh, I., Brix, A. E., French, J. E., Collins, B. J., Sanders, J. M., Vallant, M. K., & Dunnick, J. K. (2012) · Toxicologic Pathology · doi:10.1177/0192623312464304 · Cited by 20
Tatemichi, M., Tazawa, H., Masuda, M., Saleem, M., Wada, S., Donehower, L. A., Ohgaki, H., & Ohshima, H. (2004) · International Journal of Cancer · doi:10.1002/ijc.20350 · Cited by 18
Self-citationEnhancers and Suppressors of Testicular Cancer Susceptibility in Single- and Double-Mutant Mice
Lam, M.-Y., Youngren, K. K., & Nadeau, J. H. (2004) · Genetics · doi:10.1093/genetics/166.2.925 · Cited by 20
Scott, C. L., Robb, L. G., Mansfield, R., Alexander, W. S., & Begley, C. G. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00504-x · Cited by 17
Cancer-associated 53BP1 mutations induce DNA damage repair defects
Zhang, J., Yan, Z., Wang, Y., Wang, Y., Guo, X., Jing, J., Dong, X., Dong, S., Liu, X., Yu, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.033 · Cited by 17
Poon, R. Y. C. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6199-0 · Cited by 16
Vogel, P., Pletcher, J. M., & Liang, Y. (2010) · Veterinary Pathology · doi:10.1177/0300985810363484 · Cited by 16
Genetic Conflict and Apoptosis
LeGrand, E. K. (2001) · Perspectives in biology and medicine · doi:10.1353/pbm.2001.0066 · Cited by 16
The Effects of Genetic Background of Mouse Models of Cancer: Friend or Foe?Preprint
Reilly, K. M. (2016) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top076273 · Cited by 16
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
“For example, a ‘RING domain only’ isoform can be oncogenic in a mouse model [2,17]; such isoforms do not have the classic N-terminal p53 binding domain and would be non-refractory to drugs of the Nutlin class (discussed further below).”
BackgroundPetre-Lazar, B., Moreno, S. G., Livera, G., Duquenne, C., Habert, R., & Coffigny, H. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000600960019 · Cited by 15
Female embryonic lethality in Msh2–Trp53 nullizygous mice is strain dependent
Cranston, A. N., & Fishel, R. A. (1999) · Mammalian Genome · doi:10.1007/s003359901151 · Cited by 17
Ribeiro, M. F., de Oliveira, F. L., Monteiro‐Machado, M., Cardoso, P. F., Guilarducci, C. V. V., Melo, P. A., de Souza, C. M. V., & Calil-Eliás, S. (2015) · Toxicon · doi:10.1016/j.toxicon.2015.01.008 · Cited by 14
Hulla, J. E. (2001) · Carcinogenesis · doi:10.1093/carcin/22.1.89 · Cited by 14
Mapping of genetic modifiers of thymic lymphoma development in p53-knockout mice
Ochiai, Y., Tamura, Y., Saito, Y., Matsuki, A., Wakabayashi, Y., Aizawa, Y., Niwa, O., & Kominami, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206202 · Cited by 14
Creation and preliminary characterization of a Tp53 knockout rat
McCoy, A., Besch-Williford, C. L., Franklin, C. L., Weinstein, E. J., & Cui, X. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009704 · Cited by 15
A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo
Comiskey, D. F., Jacob, A. G., Sanford, B. L., Montes, M., Goodwin, A., Steiner, H. E., Matsa, E., Tapia-Santos, A. S., Bebee, T. W., Grieves, J. L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.282 · Cited by 16
Improved Embryonic Stem Cell Technologies
Drape, J. S., & Nagy, A. (2007) · Springer eBooks · doi:10.1007/978-3-540-35109-2_5 · Cited by 15
Buzard, G. S. (1996) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/s0165-1110(96)90011-1 · Cited by 13
Genetic background and tumour susceptibility in mouse models
Puccini, J., Dorstyn, L., & Kumar, S. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.35 · Cited by 13
Hirata, A., Tsukamoto, T., Yamamoto, M., Sakai, H., Yanai, T., Masegi, T., Donehower, L. A., & Tatematsu, M. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.07.022 · Cited by 12
Self-citationGhahremani, M. F., Radaelli, E., Haigh, K., Bartunkova, S., Haenebalcke, L., Marine, J., Goossens, S., & Haigh, J. J. (2014) · Cell Cycle · doi:10.4161/cc.28474 · Cited by 12
Lachance, J., Jung, L., & True, J. (2013) · G3 Genes Genomes Genetics · doi:10.1534/g3.113.007831 · Cited by 11
The Y14-p53 regulatory circuit in megakaryocyte differentiation and thrombocytopenia
Su, C.-H., Liao, W., Ke, W.-C., Yang, R., & Tarn, W. (2021) · iScience · doi:10.1016/j.isci.2021.103368 · Cited by 13
Screening strategy to generate cell specific recombination: a case report with the RIP-Cre mice
Spinelli, V., Martin, C., Dorchies, E., Vallez, E., Dehondt, H., Trabelsi, M.-S., Tailleux, A., Caron, S., & Staels, B. (2015) · Transgenic Research · doi:10.1007/s11248-015-9889-1 · Cited by 13
Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity
Biggs, P. J., Vogel, H. S., Sage, M., Martin, L. A., Donehower, L. A., & Bradley, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206384 · Cited by 12
Self-citationThe Trp53 Hemizygous Mouse in Pharmaceutical Development: Points to Consider for Pathologists
Floyd, E., Mann, P., Long, G. G., & Ochoa, R. (2002) · Toxicologic Pathology · doi:10.1080/01926230252824860 · Cited by 12
Matin, A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6433-3 · Cited by 15
Murine tumor suppressor models
Venkatachalam, S., & Donehower, L. A. (1998) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(98)00018-9 · Cited by 13
Self-citationDifferential requirements for MDM2 E3 activity during embryogenesis and in adult mice
Humpton, T. J., Nomura, K., Weber, J., Magnussen, H., Hock, A. K., Nixon, C., Dhayade, S., Stevenson, D., Huang, D. T. C., Strathdee, D., et al. (2020) · Genes & Development · doi:10.1101/gad.341875.120 · Cited by 11
Lopušná, K., Nowialis, P., Opavska, J., Abraham, A., Riva, A., Haney, S. L., & Opavský, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100285 · Cited by 12
Time to fight: targeting the circadian clock molecular machinery in cancer therapy
Astone, M., & Santoro, M. M. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.023 · Cited by 11
Mitsumori, K. (2003) · The Journal of Toxicological Sciences · doi:10.2131/jts.28.371 · Cited by 10
Petruska, J. M., Frank, D. W., Freeman, G. B., Evans, E. W., & MacDonald, J. S. (2002) · Toxicologic Pathology · doi:10.1080/01926230290166788 · Cited by 12
A novel genetic modifier of p53, mop1, results in embryonic lethality
Evans, S. C., Liang, M., Amos, C., Gu, X., & Lozano, G. (2004) · Mammalian Genome · doi:10.1007/s00335-004-2327-y · Cited by 10
Allelic Losses in Mouse Skin Tumors Induced by γ‐Irradiation of p53 Heterozygotes
Miyazawa, T., Sato, H., Hatakeyama, K., Kitagawa, T., & Kominami, R. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb02475.x · Cited by 10
Do p53 stress responses impact organismal aging?
Hasty, P., Campisi, J., & Sharp, Z. D. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.12.02 · Cited by 10
Storer, R. D., French, J. E., Donehower, L. A., Gulezian, D., Mitsumori, K., Recio, L., Schiestl, R. H., Sistare, F. D., Tamaoki, N., Usui, T., et al. (2003) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2003.07.006 · Cited by 9
Self-citationRMut: R package for a Boolean sensitivity analysis against various types of mutations
Trinh, H.-C., & Kwon, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213736 · Cited by 9
Koujitani, T., Yasuhara, K., Usui, T., Nomura, T., Onodera, H., Takagi, H., Hirose, M., & Mitsumori, K. (2000) · Cancer Letters · doi:10.1016/s0304-3835(00)00338-4 · Cited by 9
Single-Nucleotide Polymorphisms in the p53 Pathway
Harris, S. L., Gil, G. A., Hu, W., Robins, H. S., Bond, E. E., Hirshfield, K. M., Feng, Z., YU, X., Teresky, A. K., Bond, G. L., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.024 · Cited by 10
Majhi, P. D., Griner, N. B., Mayfield, J. A., Compton, S. L., Kane, J. J., Baptiste, T. A., Dunphy, K. A., Roberts, A. L., Schneider, S. S., Savage, E. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01892-5 · Cited by 9
Chromosome 11 Loss from Thymic Lymphomas Induced in Heterozygous Trp53 Mice by Phenolphthalein
Hulla, J. E. (2001) · Toxicological Sciences · doi:10.1093/toxsci/60.2.264 · Cited by 8
Madeen, E. P., Löhr, C. V., You, H. M., Siddens, L. K., Krueger, S. K., Dashwood, R. H., Gonzalez, F. J., Baird, W. M., Ho, E., Bramer, L., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22480 · Cited by 8
Genetic modifiers of p53: opportunities for breast cancer therapies
Majhi, P. D., Sharma, A., & Jerry, D. J. (2023) · Oncotarget · doi:10.18632/oncotarget.28387 · Cited by 8
Cheung, M., Menges, C. W., & Testa, J. R. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_8 · Cited by 9
Adams, C., Yu, J. S., Mao, J., Jen, K., Costes, S. V., Wade, M. R., Shoemake, J. D., Aina, O. H., Rosario, R. D., Menchavez, P. T., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22377 · Cited by 7
Mouse Models of Inherited Cancer Syndromes
Jahid, S., & Lipkin, S. M. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.08.011 · Cited by 7
Mouse Models of Intestinal Cancer
Perchiniak, E. M., & Groden, J. L. (2009) · Springer eBooks · doi:10.1007/978-0-387-09568-4_2 · Cited by 7
Hendry, J. H., Hoyes, K. P., Wadeson, P. J., & Roberts, S. A. (2002) · International Journal of Radiation Biology · doi:10.1080/09553000210132333 · Cited by 7
Mao, J., Lindsay, K. A., Mairs, R., & Wheldon, T. E. (2001) · Journal of Theoretical Biology · doi:10.1006/jtbi.2001.2300 · Cited by 6
Barkan, D., Montagna, C., Ried, T., & Green, J. E. (2004) · Wiley eBooks · doi:10.1002/0471675067.mmc007 · Cited by 7
Strain‐specific modifier genes governing craniofacial phenotypes
Mukhopadhyay, P., Brock, G. N., Webb, C. L., Pisano, M., & Greene, R. M. (2012) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.22890 · Cited by 5
Couture, O. P., Lombardi, E., Davis, K., Hays, E., & Chandar, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082494 · Cited by 6
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis
Tashakori, M., Zhang, Y., Xiong, S., You, M. J., & Lozano, G. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0346 · Cited by 6
Teitell, M. A., & Pandolfi, P. P. (2004) · Wiley eBooks · doi:10.1002/0471675067.mmc014 · Cited by 6
Kim, U., Kim, C., Oh, H., Lee, J. M., Chang, S., Ryu, B., Kim, J., Lee, H., & Park, J. (2019) · Genes & Genomics · doi:10.1007/s13258-019-00785-y · Cited by 6
Meke, F. N., Bai, Y., Ruiz-Avila, D., Carlock, C., Ayub, J., Miao, J., Hu, Y., Li, Q., & Zhang, Z. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0308 · Cited by 5
Map Making in the 21st Century: Charting Breast Cancer Susceptibility Pathways in Rodent Models
Blackburn, A. C., & Jerry, D. J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9201-9 · Cited by 5
Genome-Protective Topoisomerase 2a-Dependent G2 Arrest Requires p53 in hTERT-Positive Cancer Cells
Lockwood, N., Martini, S., Lopez-Pardo, A., Deiss, K., Segeren, H. A., Semple, R. K., Collins, I., Repana, D., Cobbaut, M., Soliman, T. N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1785 · Cited by 5
Mouse models of testicular germ cell tumors
Carouge, D., & Joseph, H. B. (2012) · InTech eBooks · doi:10.5772/38921 · Cited by 5
Scolan, E. L., Wendling, F., Barnache, S., Denis, N., Tulliez, M., Vainchenker, W., & Moreau-Gachelin, F. (2001) · Oncogene · doi:10.1038/sj.onc.1204708 · Cited by 5
Genetic background determines inflammatory angiogenesis response to dipyridamole in mice
Sampaio, F. P., Castro, P. R., Marques, S. M., Campos, P. P., Ferreira, M. A. N. D., & Andrade, S. P. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.012066 · Cited by 4
Genetically Engineered Animals in Product Discovery and Development
Galbreath, E. J., Pinkert, C. A., Bolon, B. N., & Morton, D. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415759-0.00012-1 · Cited by 4
Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice
Branca, J. A., Low, B. E., Saxl, R. L., Sargent, J. K., Doty, R. A., Wiles, M. V., Dumont, B. L., & Hasham, M. G. (2020) · Genes & Cancer · doi:10.18632/genesandcancer.198 · Cited by 4
Metadata
- Authors
- Donehower, L. A., Harvey, M., Vogel, H., McArthur, M. J., Montgomery, C. A., Park, S. H., Thompson, T., Ford, R. J., & Bradley, A.
- Affiliations
- Baylor College of Medicine (US)
- Harvard University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Donehower, Lawrence A.
- Venue
- Molecular Carcinogenesis
- Publisher
- Wiley
- Published
- 1995-09
- Volume
- 14
- Issue
- 1
- Pages
- 16-22
- ISSN
- 0899-1987 (ISSN-L)
- 1098-2744
- OpenAlex
- W2093294267
- Cited by
- 252
- References
- 20
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 11 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 7 · 2015: 8 · 2014: 6 · 2013: 9 · 2012: 12
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-50588, CA-16672, R01CA050588, CA54897, R01CA054897, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- p53 deficiency, carcinogenesis, genetic background, 129/Sv mice, malignant teratoma, thymic lymphoma, B-cell lymphoma, Li-Fraumeni syndrome, cancer susceptibility, spontaneous tumors
- MeSH terms
- Alleles, Animals, Crosses, Genetic, Disease Models, Animal, Genetic Engineering, Heterozygote, Humans, Lymphoma, Mice, Inbred C57BL, Mice, Mutant Strains, Neoplasms, Experimental, Genes, p53, Tumor Suppressor Protein p53, Li-Fraumeni Syndrome, Genetic Predisposition to Disease, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.